Here's the thing. Everyone's got their own risk tolerance, certainly do your own thing.
I'm not a fan of having to monitor for higher glucose levels, but I'm most concerned about the acceleration of undiagnosed cancer. If it were one and done, I could deal with the limited risk for long term benefit, but the visceral fat quickly returns in unless Tesa is taken continuously. GLP/GIP offer similar benefits, without the risk of a slow growing tumor somewhere getting turbocharged. That's why it's only approved for people with HIV. Everyone can benefit from reduced visceral fat, but it's only in this population is the risk considered worth it, in some part, reading between the lines, because of the severe psychological effects of simultaneous muscle loss and rapid and abnormally distributed (ie freaky looking) fat gain in HIV patients.
HIV-infected patients on highly active antiretroviral therapy (HAART) develop a complex of body composition changes known, including peripheral fat loss (lipoatrophy) and central fat accumulation (lipohypertrophy). These changes may cause ...
www.ncbi.nlm.nih.gov
"During the continuation phase of the studies, the improvement in VAT was not sustained among patients who were re-randomized to placebo after 26 weeks of therapy with tesamorelin (T-P). However, those randomized to continue tesamorelin for an additional 26 weeks (T-T) experienced a sustained reduction in VAT....
The rapid reversal of the tesamorelin effects on body fat and lipid levels upon discontinuation of therapy is probably explained by the reversal of IGF-1 increases. "